| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Baroreflex | 23 | 2019 | 84 | 3.640 |
Why?
|
| Prenatal Exposure Delayed Effects | 12 | 2019 | 92 | 2.420 |
Why?
|
| Betamethasone | 9 | 2019 | 53 | 2.260 |
Why?
|
| Heart Rate | 26 | 2020 | 335 | 2.220 |
Why?
|
| Blood Pressure | 29 | 2024 | 846 | 2.150 |
Why?
|
| Autonomic Nervous System | 10 | 2020 | 43 | 2.010 |
Why?
|
| Angiotensin I | 16 | 2019 | 241 | 2.000 |
Why?
|
| Peptide Fragments | 16 | 2019 | 398 | 1.910 |
Why?
|
| Hypertension | 16 | 2022 | 961 | 1.860 |
Why?
|
| Medulla Oblongata | 6 | 2019 | 51 | 1.540 |
Why?
|
| Glucocorticoids | 8 | 2019 | 145 | 1.400 |
Why?
|
| Oxidative Stress | 3 | 2019 | 229 | 1.280 |
Why?
|
| Orthostatic Intolerance | 5 | 2019 | 10 | 1.080 |
Why?
|
| Hemodynamics | 2 | 2019 | 155 | 0.960 |
Why?
|
| Renin-Angiotensin System | 9 | 2019 | 179 | 0.900 |
Why?
|
| Pregnancy | 17 | 2019 | 996 | 0.850 |
Why?
|
| Peptidyl-Dipeptidase A | 5 | 2013 | 132 | 0.840 |
Why?
|
| Nonverbal Communication | 2 | 2012 | 4 | 0.820 |
Why?
|
| Empathy | 2 | 2012 | 18 | 0.790 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2019 | 105 | 0.760 |
Why?
|
| Animals | 32 | 2022 | 7510 | 0.730 |
Why?
|
| Premature Birth | 5 | 2024 | 67 | 0.720 |
Why?
|
| Inositol | 1 | 2019 | 5 | 0.680 |
Why?
|
| Female | 39 | 2024 | 19999 | 0.670 |
Why?
|
| Choline | 1 | 2019 | 14 | 0.670 |
Why?
|
| Benzimidazoles | 4 | 2019 | 28 | 0.650 |
Why?
|
| Tetrazoles | 4 | 2019 | 61 | 0.640 |
Why?
|
| Male | 44 | 2024 | 19202 | 0.640 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 104 | 0.640 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2019 | 65 | 0.630 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 66 | 0.630 |
Why?
|
| Angiotensin II | 10 | 2018 | 244 | 0.590 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2008 | 40 | 0.590 |
Why?
|
| Sympathetic Nervous System | 4 | 2019 | 31 | 0.580 |
Why?
|
| Nitrates | 1 | 2017 | 27 | 0.580 |
Why?
|
| Angiotensins | 5 | 2018 | 42 | 0.550 |
Why?
|
| Antihypertensive Agents | 4 | 2019 | 352 | 0.550 |
Why?
|
| Sheep | 10 | 2018 | 233 | 0.550 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2019 | 122 | 0.540 |
Why?
|
| Renin | 6 | 2019 | 109 | 0.530 |
Why?
|
| Dietary Supplements | 1 | 2017 | 185 | 0.520 |
Why?
|
| Exercise | 2 | 2019 | 672 | 0.510 |
Why?
|
| Therapeutic Touch | 2 | 2012 | 10 | 0.500 |
Why?
|
| Meditation | 2 | 2012 | 22 | 0.500 |
Why?
|
| Allopurinol | 1 | 2014 | 12 | 0.490 |
Why?
|
| Nausea | 4 | 2018 | 53 | 0.490 |
Why?
|
| Rats | 13 | 2019 | 1592 | 0.480 |
Why?
|
| Proteinuria | 1 | 2014 | 59 | 0.480 |
Why?
|
| Infant, Very Low Birth Weight | 6 | 2019 | 49 | 0.470 |
Why?
|
| Citalopram | 1 | 2014 | 6 | 0.470 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2014 | 11 | 0.470 |
Why?
|
| Brain Chemistry | 1 | 2014 | 29 | 0.460 |
Why?
|
| Disease Models, Animal | 9 | 2019 | 1020 | 0.460 |
Why?
|
| Fetal Development | 3 | 2018 | 26 | 0.450 |
Why?
|
| Adolescent | 18 | 2024 | 3568 | 0.450 |
Why?
|
| Depressive Disorder, Major | 1 | 2014 | 42 | 0.450 |
Why?
|
| Kidney | 7 | 2023 | 518 | 0.450 |
Why?
|
| Age Factors | 7 | 2020 | 1187 | 0.440 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 163 | 0.430 |
Why?
|
| Vasopressins | 4 | 2018 | 17 | 0.420 |
Why?
|
| Time | 1 | 2012 | 23 | 0.410 |
Why?
|
| Touch | 1 | 2012 | 37 | 0.400 |
Why?
|
| Infant, Premature | 4 | 2019 | 69 | 0.400 |
Why?
|
| Temporal Lobe | 3 | 2017 | 30 | 0.400 |
Why?
|
| Heart | 3 | 2020 | 176 | 0.400 |
Why?
|
| Vagus Nerve | 4 | 2019 | 29 | 0.390 |
Why?
|
| Heart Failure | 2 | 2017 | 639 | 0.390 |
Why?
|
| Humans | 35 | 2024 | 32082 | 0.390 |
Why?
|
| Tilt-Table Test | 5 | 2018 | 13 | 0.380 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 3 | 2015 | 8 | 0.380 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2019 | 742 | 0.370 |
Why?
|
| Gestational Age | 5 | 2019 | 121 | 0.360 |
Why?
|
| Behavior, Animal | 1 | 2011 | 249 | 0.330 |
Why?
|
| Receptor, Angiotensin, Type 1 | 4 | 2013 | 65 | 0.320 |
Why?
|
| Allostasis | 3 | 2017 | 12 | 0.310 |
Why?
|
| Sex Factors | 6 | 2019 | 667 | 0.310 |
Why?
|
| Rats, Transgenic | 6 | 2019 | 47 | 0.310 |
Why?
|
| Solitary Nucleus | 3 | 2015 | 34 | 0.300 |
Why?
|
| Infant, Newborn | 8 | 2024 | 673 | 0.290 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2017 | 47 | 0.280 |
Why?
|
| Sodium | 2 | 2024 | 40 | 0.280 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2019 | 31 | 0.270 |
Why?
|
| Pilot Projects | 5 | 2019 | 547 | 0.270 |
Why?
|
| Brain | 5 | 2019 | 948 | 0.260 |
Why?
|
| Hydrocortisone | 2 | 2019 | 57 | 0.260 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2019 | 85 | 0.260 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2019 | 85 | 0.260 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2005 | 10 | 0.260 |
Why?
|
| Stress, Psychological | 2 | 2024 | 222 | 0.240 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2023 | 33 | 0.220 |
Why?
|
| Pressoreceptors | 1 | 2003 | 6 | 0.220 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 44 | 0.220 |
Why?
|
| Fludrocortisone | 2 | 2014 | 6 | 0.220 |
Why?
|
| Cyclosporine | 1 | 2003 | 49 | 0.220 |
Why?
|
| Sodium, Dietary | 1 | 2022 | 23 | 0.210 |
Why?
|
| Dyspepsia | 1 | 2022 | 1 | 0.210 |
Why?
|
| Neprilysin | 4 | 2013 | 31 | 0.200 |
Why?
|
| Relaxation | 2 | 2012 | 9 | 0.200 |
Why?
|
| Gastroparesis | 1 | 2022 | 10 | 0.200 |
Why?
|
| Child | 6 | 2019 | 2439 | 0.200 |
Why?
|
| Sheep, Domestic | 2 | 2019 | 18 | 0.190 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 240 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2019 | 37 | 0.190 |
Why?
|
| Up-Regulation | 2 | 2019 | 189 | 0.190 |
Why?
|
| Drug Design | 2 | 2019 | 43 | 0.190 |
Why?
|
| Angiotensinogen | 2 | 2019 | 59 | 0.190 |
Why?
|
| Piperidines | 2 | 2019 | 118 | 0.180 |
Why?
|
| Fetus | 2 | 2019 | 86 | 0.180 |
Why?
|
| Case-Control Studies | 2 | 2019 | 895 | 0.170 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2022 | 28 | 0.170 |
Why?
|
| Young Adult | 4 | 2024 | 2665 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 1128 | 0.170 |
Why?
|
| Saliva | 1 | 2019 | 36 | 0.170 |
Why?
|
| Acoustic Stimulation | 2 | 2017 | 126 | 0.170 |
Why?
|
| Supine Position | 1 | 2019 | 10 | 0.170 |
Why?
|
| Patient Positioning | 1 | 2019 | 23 | 0.170 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 14 | 0.160 |
Why?
|
| Prenatal Care | 1 | 2019 | 51 | 0.160 |
Why?
|
| Aging | 3 | 2015 | 943 | 0.160 |
Why?
|
| Organophosphorus Compounds | 1 | 2019 | 33 | 0.160 |
Why?
|
| Enzyme Activation | 1 | 2019 | 135 | 0.160 |
Why?
|
| Acetylcholine | 1 | 2019 | 48 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2022 | 461 | 0.160 |
Why?
|
| Physical Fitness | 1 | 2019 | 131 | 0.160 |
Why?
|
| Homeostasis | 1 | 2019 | 132 | 0.160 |
Why?
|
| Prospective Studies | 5 | 2024 | 2282 | 0.150 |
Why?
|
| Continental Population Groups | 1 | 2019 | 237 | 0.150 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2017 | 3 | 0.150 |
Why?
|
| Fungi | 1 | 2017 | 7 | 0.150 |
Why?
|
| Electroencephalography | 1 | 2017 | 72 | 0.150 |
Why?
|
| Edema | 1 | 2017 | 28 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 18 | 0.150 |
Why?
|
| Nitrites | 1 | 2017 | 21 | 0.150 |
Why?
|
| Beta vulgaris | 1 | 2017 | 11 | 0.150 |
Why?
|
| Antifungal Agents | 1 | 2017 | 40 | 0.150 |
Why?
|
| Adult | 6 | 2024 | 9375 | 0.140 |
Why?
|
| Physical Endurance | 1 | 2017 | 35 | 0.140 |
Why?
|
| Bacteria | 1 | 2017 | 48 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 72 | 0.140 |
Why?
|
| Military Personnel | 1 | 2017 | 92 | 0.140 |
Why?
|
| Oxygen | 1 | 2017 | 142 | 0.140 |
Why?
|
| Mental Health | 2 | 2020 | 119 | 0.140 |
Why?
|
| Overweight | 1 | 2018 | 280 | 0.140 |
Why?
|
| Birth Weight | 3 | 2023 | 47 | 0.130 |
Why?
|
| Aldosterone | 1 | 2015 | 26 | 0.130 |
Why?
|
| Catecholamines | 1 | 2015 | 18 | 0.130 |
Why?
|
| Hypotension, Orthostatic | 1 | 2015 | 13 | 0.130 |
Why?
|
| Cognition | 1 | 2020 | 556 | 0.130 |
Why?
|
| Syncope | 1 | 2015 | 26 | 0.130 |
Why?
|
| Dominance, Cerebral | 1 | 2015 | 10 | 0.130 |
Why?
|
| Neurons | 1 | 2019 | 407 | 0.130 |
Why?
|
| Inflammation | 1 | 2019 | 529 | 0.120 |
Why?
|
| Antimetabolites | 1 | 2014 | 11 | 0.120 |
Why?
|
| Endocannabinoids | 1 | 2015 | 35 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 2019 | 327 | 0.120 |
Why?
|
| Vascular Diseases | 1 | 2015 | 66 | 0.120 |
Why?
|
| Fructose | 1 | 2014 | 11 | 0.120 |
Why?
|
| Rats, Wistar | 1 | 2014 | 79 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2015 | 54 | 0.120 |
Why?
|
| Resistance Training | 1 | 2015 | 82 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 322 | 0.120 |
Why?
|
| Analysis of Variance | 5 | 2016 | 462 | 0.120 |
Why?
|
| Mineralocorticoids | 1 | 2014 | 5 | 0.120 |
Why?
|
| Stomach Diseases | 1 | 2014 | 7 | 0.120 |
Why?
|
| Abdominal Pain | 1 | 2014 | 44 | 0.120 |
Why?
|
| Stroke Volume | 1 | 2017 | 348 | 0.120 |
Why?
|
| Caloric Restriction | 1 | 2015 | 106 | 0.120 |
Why?
|
| Middle Aged | 5 | 2022 | 11834 | 0.110 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 493 | 0.110 |
Why?
|
| Choroid Plexus | 1 | 2013 | 3 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1428 | 0.110 |
Why?
|
| Anxiety | 1 | 2014 | 191 | 0.100 |
Why?
|
| Reading | 1 | 2012 | 5 | 0.100 |
Why?
|
| Love | 1 | 2012 | 4 | 0.100 |
Why?
|
| North Carolina | 4 | 2018 | 1538 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 629 | 0.100 |
Why?
|
| Respiratory Rate | 1 | 2012 | 13 | 0.100 |
Why?
|
| Psychophysiology | 1 | 2011 | 2 | 0.100 |
Why?
|
| Rest | 1 | 2012 | 53 | 0.100 |
Why?
|
| Extremities | 1 | 2012 | 50 | 0.100 |
Why?
|
| Nitric Oxide | 2 | 2011 | 111 | 0.100 |
Why?
|
| Animals, Newborn | 1 | 2012 | 112 | 0.100 |
Why?
|
| Depression | 1 | 2015 | 445 | 0.100 |
Why?
|
| Animals, Suckling | 1 | 2011 | 4 | 0.100 |
Why?
|
| Sucking Behavior | 1 | 2011 | 4 | 0.100 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2011 | 11 | 0.100 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2011 | 19 | 0.100 |
Why?
|
| Hydronephrosis | 1 | 2011 | 12 | 0.100 |
Why?
|
| Kidney Medulla | 1 | 2011 | 29 | 0.090 |
Why?
|
| Creatinine | 2 | 2024 | 196 | 0.090 |
Why?
|
| Receptors, Angiotensin | 1 | 2011 | 61 | 0.090 |
Why?
|
| Hypotension | 1 | 2011 | 47 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 99 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2012 | 288 | 0.090 |
Why?
|
| Time Factors | 4 | 2020 | 2145 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 1542 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 2 | 2023 | 308 | 0.090 |
Why?
|
| Neurotransmitter Agents | 1 | 2010 | 26 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2018 | 923 | 0.090 |
Why?
|
| Aged | 3 | 2020 | 10308 | 0.090 |
Why?
|
| Reactive Oxygen Species | 3 | 2019 | 157 | 0.090 |
Why?
|
| Leptin | 1 | 2009 | 71 | 0.080 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2009 | 22 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2263 | 0.080 |
Why?
|
| Exercise Test | 2 | 2019 | 225 | 0.080 |
Why?
|
| Microinjections | 3 | 2015 | 35 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2015 | 3304 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 1176 | 0.070 |
Why?
|
| Fetal Organ Maturity | 2 | 2016 | 7 | 0.070 |
Why?
|
| Epinephrine | 2 | 2017 | 40 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2015 | 507 | 0.070 |
Why?
|
| Iodine Radioisotopes | 1 | 2006 | 16 | 0.070 |
Why?
|
| C-Reactive Protein | 2 | 2017 | 238 | 0.070 |
Why?
|
| Norepinephrine | 2 | 2017 | 77 | 0.070 |
Why?
|
| Risk Factors | 3 | 2019 | 3880 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 135 | 0.060 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2005 | 1 | 0.060 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2005 | 9 | 0.060 |
Why?
|
| Fasting | 1 | 2005 | 95 | 0.060 |
Why?
|
| Heparin | 1 | 2005 | 73 | 0.060 |
Why?
|
| Mice | 3 | 2019 | 2474 | 0.060 |
Why?
|
| Natriuresis | 1 | 2024 | 5 | 0.060 |
Why?
|
| European Continental Ancestry Group | 2 | 2019 | 1165 | 0.060 |
Why?
|
| Testosterone | 1 | 2003 | 48 | 0.050 |
Why?
|
| Kidney Cortex | 1 | 2022 | 25 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2014 | 406 | 0.050 |
Why?
|
| Gastric Emptying | 1 | 2022 | 4 | 0.050 |
Why?
|
| Water | 1 | 2022 | 56 | 0.050 |
Why?
|
| Papio | 1 | 2022 | 91 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2016 | 1816 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2019 | 680 | 0.050 |
Why?
|
| African Americans | 2 | 2019 | 1424 | 0.050 |
Why?
|
| Macaca fascicularis | 1 | 2022 | 434 | 0.040 |
Why?
|
| Diet | 1 | 2022 | 390 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 3990 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2019 | 108 | 0.040 |
Why?
|
| Semicarbazides | 1 | 2019 | 1 | 0.040 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2019 | 2 | 0.040 |
Why?
|
| PC12 Cells | 1 | 2019 | 6 | 0.040 |
Why?
|
| Reference Values | 2 | 2010 | 246 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2019 | 15 | 0.040 |
Why?
|
| Random Allocation | 2 | 2010 | 227 | 0.040 |
Why?
|
| Triazoles | 1 | 2019 | 14 | 0.040 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2019 | 31 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 98 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 371 | 0.040 |
Why?
|
| Cardiovascular System | 1 | 2019 | 43 | 0.040 |
Why?
|
| Memory | 1 | 2020 | 190 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 581 | 0.040 |
Why?
|
| Placenta | 1 | 2019 | 74 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2017 | 33 | 0.040 |
Why?
|
| Cell Line | 1 | 2019 | 435 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2017 | 30 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2019 | 3505 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2017 | 59 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2017 | 33 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 80 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 400 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 770 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 80 | 0.040 |
Why?
|
| Mitochondria | 1 | 2019 | 185 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 73 | 0.040 |
Why?
|
| Uric Acid | 1 | 2017 | 27 | 0.040 |
Why?
|
| Veterans | 1 | 2017 | 68 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2017 | 246 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 448 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 472 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1496 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 36 | 0.030 |
Why?
|
| Posture | 1 | 2015 | 55 | 0.030 |
Why?
|
| Cholesterol | 1 | 2017 | 252 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 99 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 107 | 0.030 |
Why?
|
| Diastole | 1 | 2015 | 96 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 684 | 0.030 |
Why?
|
| Glycerides | 1 | 2015 | 13 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 39 | 0.030 |
Why?
|
| Neurophysiology | 1 | 2015 | 10 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 90 | 0.030 |
Why?
|
| Arachidonic Acids | 1 | 2015 | 23 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 604 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2015 | 17 | 0.030 |
Why?
|
| Body Composition | 1 | 2017 | 396 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 783 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 315 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2015 | 67 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 102 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2015 | 56 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 263 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 97 | 0.030 |
Why?
|
| Phenanthrolines | 1 | 2013 | 3 | 0.030 |
Why?
|
| p-Chloromercuribenzoic Acid | 1 | 2013 | 3 | 0.030 |
Why?
|
| Phenylmercuric Acetate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 43 | 0.030 |
Why?
|
| Edetic Acid | 1 | 2013 | 8 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2013 | 86 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 560 | 0.030 |
Why?
|
| Dopamine | 1 | 2015 | 232 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 142 | 0.030 |
Why?
|
| Cyclic N-Oxides | 1 | 2012 | 8 | 0.030 |
Why?
|
| Spin Labels | 1 | 2012 | 24 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 1 | 2012 | 17 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2012 | 18 | 0.030 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2012 | 29 | 0.030 |
Why?
|
| Injections | 1 | 2012 | 64 | 0.030 |
Why?
|
| Pediatrics | 1 | 2014 | 155 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2012 | 63 | 0.030 |
Why?
|
| Chromones | 1 | 2011 | 5 | 0.020 |
Why?
|
| Antioxidants | 1 | 2012 | 114 | 0.020 |
Why?
|
| Androstadienes | 1 | 2011 | 17 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 337 | 0.020 |
Why?
|
| Weight Loss | 1 | 2015 | 480 | 0.020 |
Why?
|
| Morpholines | 1 | 2011 | 37 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2011 | 118 | 0.020 |
Why?
|
| United States | 1 | 2020 | 3975 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 881 | 0.020 |
Why?
|
| Losartan | 1 | 2011 | 64 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 61 | 0.020 |
Why?
|
| Neurochemistry | 1 | 2010 | 3 | 0.020 |
Why?
|
| Bradycardia | 1 | 2009 | 16 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 83 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2010 | 47 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 159 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2010 | 100 | 0.020 |
Why?
|
| Autoradiography | 1 | 2009 | 45 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 51 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2009 | 35 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 534 | 0.020 |
Why?
|
| Protein Binding | 1 | 2009 | 201 | 0.020 |
Why?
|